News

The ten-year indefinite delivery/indefinite quantity contract will see DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, supporting and conducting Phase I clinical trials of infectious

Based on the antioxidant supplement used in The National Eye Institute’s (NEI) AREDS 2 study, ProVision leverages today’s best research on nutritional support for macular health to create

Phoxillum, a pre-mixed solution containing phosphate in a 5l bag, is designed to treat hypophosphatemia in patients receiving CRRT, such as in an intensive care environment for patients

Deflazacort is a glucocorticoid with anti-inflammatory and immunosuppressant properties. Currently, there are no approved therapies for DMD in the US, where it affects around 20,000 people. The company

Administered as a once-daily single injection independently of meals, Xultophy is a combination of basal insulin Tresiba (insulin degludec) and GLP-1 analogue Victoza (liraglutide). The product is intended

The injection is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. The drug is claimed to be the first approved by the

Solasia is currently completing a Phase I study of darinaparsin in Japan and South Korea to treat patients with relapsed and refractory peripheral T-cell lymphoma (hereinafter "PTCL"). Solasia

The new partnership with Janssen brings to nine the number of pharmaceutical companies around CQDM’s table, increasing the financial leverage that partners generate together. Thanks to CQDM’s unique

This NIH/National Institute of Neurological Disorders and Stroke (NINDS) award will support NIH’s Drug Manufacturing and Formulation Program (DMFP), which is a component of the Blueprint Neurotherapeutics Network